Rare / Genetic Disease

Addressing the Economic and
Operational Issues of the
Clinical Practice Gaps in NSCLC

This paper presents five key recommendations to tackle economic and operational barriers hindering access to precision medicine for NSCLC patients.

The Clinical Practice Gaps in Precision Medicine

Discover What’s Changed Since the Original 64.4% Insight. The Updated Clinical Practice Gaps Report Is Here.

Practice Gaps Webinar Series

Dive into our series of expert-led webinars, where we break down the seven practice gaps derailing precision medicine and reveal how to overcome them across the patient journey.

The Impact of Clinical Practice Gaps

Our first Practice Gaps study, revealing that 64.4% of patients don't receive the best treatment for them.

Strategic Diagnostics in Action

Diaceutics accelerated gene therapy access by implementing a global strategy, reducing test result turnaround times from 28 days to 1 week and enhancing patient identification.

Linking Rare Disease Patients to Targeted Therapies

Diaceutics connects rare disease patients to targeted therapies through advanced patient identification, improving access to care and accelerating clinical trial enrollment.

D-Cubed Full report 2025

Explore D-Cubed Pharma's comprehensive report on how Diagnostics, Data, and Digital transform pharma launch performance and patient access in 2026 and beyond.

Timely Peer Education to Overcome Clinical Hesitation in Rare Oncology

Timely peer education improved HCP engagement and confidence in rare oncology therapy, enhancing diagnostic understanding and accelerating patient access.

Driving Physician Engagement in a Rare Pediatric Disease Through Real-World Data and Precision Outreach

Discover how Physician Engage helped a top global pharma compnay generate $2 million in revenue for their project.

Join us at Fierce Pharma Week

Join us at Fierce Pharma Week to explore innovative diagnostic-driven therapy commercialization strategies. Engage with experts and discover how real-world data can enhance HCP engagement.

We're attending Fierce Pharma Week